Overview: HLA Allopurinol Hypersensitivity TestIntroduction: The HLA Allopurinol Hypersensitivity Test detects HLA-B5801 to assess allopurinol hypersensitivity risk, preventing severe skin reactions. Following 2023 ACR guidelines, it uses PCR for high specificity, supporting drug sensitivity screening. This test is critical for guiding safe allopurinol therapy, avoiding severe cutaneous reactions, and improving outcomes in pharmacogenomics for patients with gout or hyperuricemia.Other Names: HLA-B5801 Assay, Allopurinol Sensitivity Test.FDA Status: Laboratory-developed test (LDT), meeting pharmacogenomics standards for diagnostic accuracy.Historical Milestone: HLA-B5801 testing began in the 2000s after allopurinol hypersensitivity was linked to this allele. PCR-based assays improved screening accuracy.Purpose: Assesses HLA-B5801 for allopurinol hypersensitivity risk, guides safe therapy, and prevents severe skin reactions in patients with gout.Test Parameters: 1. HLA-B58:01Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva at any time. Report history of gout, drug allergies, or family history of hypersensitivity.Specimen: 2-5 mL whole blood (EDTA), 1-2 buccal swabs (sterile swab), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.Sample Stability at Room Temperature: 24 hoursSample Stability at Refrigeration: 48 hoursSample Stability at Frozen: Not frozenMedical History: Document history of gout, drug allergies, or family history of hypersensitivity reactions. Include current medications, especially urate-lowering therapies.Consent: Written consent required, detailing the tests purpose, hypersensitivity implications, and potential need for alternative therapy.Procedural Considerations: Uses PCR to detect HLA-B5801. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often before allopurinol initiation.Factors Affecting Result Accuracy: Improper sample handling or contamination can affect results. Low DNA quality may impact typing accuracy.Clinical Significance: Positive HLA-B5801 indicates high allopurinol hypersensitivity risk, prompting alternative therapy (e.g., febuxostat). Negative results suggest safe allopurinol use but require monitoring.Specialist Consultation: Consult a rheumatologist or pharmacogenomicist for result interpretation and therapy planning.Additional Supporting Tests: Uric acid levels, renal function tests, or skin patch testing to assess gout and drug sensitivity.Test Limitations: Limited to HLA-B5801; other hypersensitivity causes may exist. Clinical correlation is needed.References: ACR Gout Guidelines, 2023; Clinical Pharmacogenetics, Hung SI, 2022.